Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 When less is more

Literature DB >> 28387051

When less is more - efficacy with less toxicity at the ED50.

Simon Dimmitt^1,2, Hans Stampfer^3,4, Jennifer H Martin^5,6.

Abstract

Entities: Disease

Keywords: dose-response; effective dose 50; pharmaceutical marketing

Mesh：

Year: 2017 PMID： 28387051 PMCID： PMC5465328 DOI： 10.1111/bcp.13281

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

27 in total

1. Surrogate end-points in clinical practice: are we providing worse care?

Authors: J H Martin; M F Fay
Journal: Intern Med J Date: 2010-06 Impact factor: 2.048

2. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey.

Authors: Johannes P Mouton; Ushma Mehta; Andy G Parrish; Douglas P K Wilson; Annemie Stewart; Christine W Njuguna; Nicole Kramer; Gary Maartens; Marc Blockman; Karen Cohen
Journal: Br J Clin Pharmacol Date: 2015-07-06 Impact factor: 4.335

3. Effects of torcetrapib in patients at high risk for coronary events.

Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245

4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors:
Journal: Lancet Date: 1994-11-19 Impact factor: 79.321

5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors:
Journal: N Engl J Med Date: 1998-11-05 Impact factor: 91.245

Review 6. Aspirin dose for the prevention of cardiovascular disease: a systematic review.

Authors: Charles L Campbell; Susan Smyth; Gilles Montalescot; Steven R Steinhubl
Journal: JAMA Date: 2007-05-09 Impact factor: 56.272

7. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

Authors: Marvin A Konstam; James D Neaton; Kenneth Dickstein; Helmut Drexler; Michel Komajda; Felipe A Martinez; Gunter A J Riegger; William Malbecq; Ronald D Smith; Soneil Guptha; Philip A Poole-Wilson
Journal: Lancet Date: 2009-11-16 Impact factor: 79.321

Review 8. Bariatric surgery: a systematic review and meta-analysis.

Authors: Henry Buchwald; Yoav Avidor; Eugene Braunwald; Michael D Jensen; Walter Pories; Kyle Fahrbach; Karen Schoelles
Journal: JAMA Date: 2004-10-13 Impact factor: 56.272

9. Effects of intensive glucose lowering in type 2 diabetes.

Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245

10. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.

Authors: Jorie Versmissen; Daniëlla M Oosterveer; Mojgan Yazdanpanah; Joep C Defesche; Dick C G Basart; Anho H Liem; Jan Heeringa; Jacqueline C Witteman; Peter J Lansberg; John J P Kastelein; Eric J G Sijbrands
Journal: BMJ Date: 2008-11-11

8 in total

Review 1. Why maximum tolerated dose?

Authors: Hans G Stampfer; Genevieve M Gabb; Simon B Dimmitt
Journal: Br J Clin Pharmacol Date: 2019-07-22 Impact factor: 4.335

2. Cannabinoid use in practice in Australasia-Better guidance and new drug information systems will be essential for prescribers.

Authors: Jennifer H Martin; Nicholas J Talley
Journal: Br J Clin Pharmacol Date: 2019-05-23 Impact factor: 4.335

When less is more - efficacy with less toxicity at the ED50.

1. Surrogate end-points in clinical practice: are we providing worse care?

2. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey.

3. Effects of torcetrapib in patients at high risk for coronary events.

4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Review 6. Aspirin dose for the prevention of cardiovascular disease: a systematic review.

7. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

Review 8. Bariatric surgery: a systematic review and meta-analysis.

9. Effects of intensive glucose lowering in type 2 diabetes.

10. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.

Review 1. Why maximum tolerated dose?

2. Cannabinoid use in practice in Australasia-Better guidance and new drug information systems will be essential for prescribers.

Review 3. Antithrombotic dose: Some observations from published clinical trials.

Review 4. The pharmacodynamic and clinical trial evidence for statin dose.

Review 5. Optimising low-dose methotrexate for rheumatoid arthritis-A review.

Review 6. Artificial intelligence to deep learning: machine intelligence approach for drug discovery.

7. Synergistic effect of ursolic acid and piperine in CCl₄ induced hepatotoxicity.

8. Effective dose 50 method as the minimal clinically important difference: Evidence from depression trials.